The Assessment of Muscle Strength and Cardiorespiratory Parameters Using Simple Tests in Older Adults With Recovery From Mild COVID-19

Article information

Ann Rehabil Med. 2024;48(6):389-395
Publication date (electronic) : 2024 December 10
doi : https://doi.org/10.5535/arm.240033
1Department of Physical Therapy, School of Allied Health Sciences, University of Phayao, Phayao, Thailand
2Unit of Excellence of Human Performance and Rehabilitations, University of Phayao, Phayao, Thailand
3Department of Traditional Chinese Medicine, School of Public Health, University of Phayao, Phayao, Thailand
Correspondence: Patchareeya Amput Department of Physical Therapy, School of Allied Health Sciences, University of Phayao, 19, Mae Ka, Mueang Phayao District, Phayao 56000, Thailand. Tel: +66-54-466697 Fax: +66-54-466697 E-mail: patchareeya.am@up.ac.th
Received 2024 March 14; Revised 2024 September 27; Accepted 2024 November 6.

Abstract

Objective

To evaluate muscle strength and cardiorespiratory parameters, this study uses simple tests in older adults, including those who have and have not recovered from mild coronavirus disease 2019 (COVID-19).

Methods

Eighty older adults (age≥60 years old) were divided into two groups: those without previous COVID-19 (control group, n=40) and those with recovery from mild COVID-19 (recovered group, n=40). Muscle strength was assessed using a handgrip strength test and the sit-to-stand test (STS10). Cardiorespiratory parameters were evaluated with a 1-minute sit-to-stand (1-min STS) test and a 6-minute walk test (6MWT).

Results

Both groups had normal values for body mass index, blood pressure, heart rate, and pulse oxygen saturation. The recovered group showed significant differences in handgrip strength test (24.73±6.99 vs. 22.03±4.36, p=0.041) and duration for the STS10 (25.15±6.11 vs. 33.40±7.56, p<0.001) when compared to the control group. Furthermore, the recovered group had significantly decreased repetitions of a 1-min STS (31.38±4.89 vs. 21.25±3.64, p<0.001) and increased the rate of perceived exertion (RPE) (7.43±1.20 vs. 8.95±1.01, p=0.01) and leg fatigue (1.49±1.13 vs. 3.00±1.04, p=0.03) after performing a 1-min STS when compared with the control group. Moreover, the recovered group had also significantly decreased distances for the 6MWT (421.68±8.28 vs. 384.35±6.17, p<0.001) and increased the post-test RPE (7.63±1.37 vs. 12.05±1.63, p<0.001) and the post-test leg fatigue (1.71±0.88 vs. 5.28±0.91, p<0.001) compared with the control group.

Conclusion

Older adults with recovery from mild COVID-19 reported reduced muscle strength and exercise tolerance when compared with older adults without COVID-19.

GRAPHICAL ABSTRACT

INTRODUCTION

Coronavirus disease 2019 (COVID-19) is an infectious state characterized by rapid person-to-person transmission. It leads to clinical symptoms such as fever, acute respiratory failure, and pneumonia [1]. In addition, COVID-19 causes musculoskeletal disorders including fatigue, myalgia, arthralgia, muscle weakness, and muscle soreness [2-4]. These outcomes occur due to the COVID-19 virus-induced spectrum of myopathic changes via severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) binding to the angiotensin-converting enzyme 2 (ACE2) receptor on the surface of the skeletal muscle cells [5,6]. Furthermore, SARS-CoV-2 can also cause inflammatory processes on the skeletal muscle tissue [6]. Therefore, COVID-19 patients could present with myalgia and fatigue due to these inflammatory processes [7]. A previous study has reported that muscle atrophy and myofiber necrosis were found in severe acute respiratory syndrome patients [8].

Additionally, these symptoms could present after the end of a COVID-19 infection, known as post-COVID-19 [9]. Fatigue, dyspnea, anosmia, and headache are the most common symptoms found in post-COVID-19 [10-12]. Fatigue is found with high frequency among musculoskeletal symptoms in individuals with post-COVID-19, resulting in intolerance to physical activities and a difficult return to normal daily life [13-15].

Several studies showed that female sex, high body mass index (BMI), presenting underlying diseases, decreased physical activity and functional status, and age is one of the most important risk factors for post-COVID-19 [3,16-19]. A previous study found that hospitalized patients recovering from COVID-19 pneumonia who had no locomotor disability before the infection showed decreased skeletal muscle strength and physical performance [20]. Interestingly, older adults had a higher risk of musculoskeletal disorders during post-COVID-19. These results may be due to the combined effect of SARS-CoV-2 infection and previous age-related reductions in muscle function and mass [21]. In addition, muscle strength and cardiorespiratory parameters in older adults with recovery from mild COVID-19 have not been reported.

Therefore, this study aims to evaluate muscle strength using the handgrip strength test and to the sit-to-stand test (STS10) and assess cardiorespiratory parameters using the 1-minute sit-to-stand (1-min STS) test and 6-minute walk test (6MWT) in older adults with recovery from mild COVID-19. These results may help to determine muscle strength and cardiorespiratory parameters in these populations.

METHODS

Study design and participants

A cross-sectional and prospective study was conducted to evaluate muscle strength using the handgrip strength test and STS10 and to assess cardiorespiratory parameters using the 1-min STS test and 6MWT in older adults with and without recovery from mild COVID-19. All participants were recruited based on the inclusion criteria, and the physical assessments, including hand grip strength, the 6MWT, and the 1-min STS, were conducted after the participants had been included in the study. These assessments were part of the data collection process and were not based on pre-existing data. The present study was approved by the Clinical Research Ethics Committee of the University of Phayao, Phayao, Thailand. The IRB code was 1.3/032/65. All participants gave written informed consent after being fully informed about the purpose and methods of the study. A total of 80 older adults with and without recovery from mild COVID-19 were recruited, and divided into two groups (n=40/group): those who have recovered from mild COVID-19 (referred to as the “recovered group”) and those who never had COVID-19 (referred to as the “control group”). The sample size was calculated using a power of 0.80, power analysis with an alpha of 0.05, and the effect size d of 0.32 [22]. Inclusion criteria were as follows: subjects who were 60 years old with recovery from mild COVID-19 and had polymerase chain reaction or antigen test kit confirmed infection with SARS-CoV-2 at least 3 months before the evaluation procedure, had mild symptoms of COVID-19 such as fever, cough, nausea, headaches, coryza, malaise, sore throat, and/or muscle aches, and subjects who were 60 years old without COVID-19 infection, All subjects had normal BMI values (18.5–24.9 kg/m2) [23], a respiratory rate at rest of fewer than 22 beats per minute, pulse oximetry at rest of more than 94%, and were able to stand and walk without assistive walking devices. Exclusion criteria were as follows: subjects who had problems with vision, communication, hearing, and musculoskeletal impairment limiting the ability to perform the activities of daily life.

Procedures

The control group and recovered group were evaluated via the handgrip strength test, STS10 test, 1-min STS test, and 6MWT. There was a 30-minute interval between each test.

In the handgrip strength test protocol, subjects were instructed to position themselves standing with the elbow extended at the moment of the test. Three consecutive repetitions of 3 seconds, with 15 seconds of rest between the repetitions, were performed with the dominant arm. The highest peak force was recorded [24].

In the STS10 test protocol, subjects were instructed to stand up until the hips and knees were fully extended and then to sit down as the arms were folded across the chest. Subsequently, subjects were asked to perform this move as fast as possible ten times. The time required to complete the test was recorded [24].

In the 1-min STS test protocol, subjects were instructed to stand up until the hips and knees were fully extended, and then to sit down while the arms were folded across the chest. After that, subjects were instructed to perform this move repeatedly as fast as possible for 1 minute. The number of completed actions during the test was recorded [24]. Each subject was investigated and the cardiorespiratory parameters of systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), pulse oxygen saturation (SpO2), rate of perceived exertion (RPE) (Borg rating of perceived exertion scale; 6–20 scales), and leg fatigue (Borg CR10 scale) were recorded before performing the test.

In the 6MWT protocol, subjects were asked to wear comfortable clothing and shoes. Before the test, each subject was instructed to sit on a chair and breathe normally for 30 minutes. Each subject performed the 6MWT. The subjects walked as fast as possible without running for the six minutes of the test duration, continuing at the same pace without stopping. The distance completed in each 6MWT was recorded [25]. Each subject was investigated and the cardiorespiratory parameters of SBP, DBP, HR, SpO2, RPE (Borg rating of perceived exertion scale; 6–20 scales), and leg fatigue (Borg CR10 scale) were recorded before performing the test. Cardiorespiratory parameters were recorded after the 1-min STS test and the 6MWT, respectively.

Statistical analysis

Descriptive statistics were used to present demographic data. An independent sample t-test was used to compare the parameters of handgrip strength, STS10, 1-min STS, and 6MWT between older adults with and without recovery from mild COVID-19. IBM SPSS Statistics software version 22.0 (IBM Corp.), was used in this study, with a p-value of less than 0.05 set to denote significance.

RESULTS

The characteristics of the subjects are shown in Table 1. The results showed that the control group and recovered group had normal values of BMI (18.5–24.9 kg/m2), blood pressure, HR, and SpO2.

Characteristics of the older adults with and without recovery from mild COVID-19

All subjects completed the handgrip strength test (kg) and STS10 test (seconds). The recovered group showed significantly decreased performance in the handgrip strength test (24.73±6.99 vs. 22.03±4.36, p=0.041) and increased a duration for the STS10 test (25.15±6.11 vs. 33.40±7.56, p<0.001) when compared to control group (Table 2).

The comparison between muscle strength, repetitions of a 1-min STS, and distance of the 6MWT in older adults with and without recovery from mild COVID-19

After performing the 1-min STS, the recovered group had significantly decreased the repetitions of a 1-min STS (number) (31.38±4.89 vs. 21.25±3.64, p<0.001) and increased the RPE (7.43±1.20 vs. 8.95±1.01, p=0.01) and leg fatigue (1.49±1.13 vs. 3.00±1.04, p=0.03) when compared with the control group. However, blood pressure, HR, and SpO2 were not different between groups (Table 3).

Impacts of 1-min STS and 6MWT on cardiorespiratory parameters in older adults with and without recovery from mild COVID-19

In post-performance of the 6MWT, the recovered group had significantly decreased distance for the 6MWT (m) (421.68±8.28 vs. 384.35±6.17, p<0.001) and increased the RPE (7.63±1.37 vs. 12.05±1.63, p<0.001) and leg fatigue (1.71±0.88 vs. 5.28±0.91, p<0.001) when compared to control group. The results are shown in Table 3.

DISCUSSION

This study points out that recovered group showed decreased upper limb and lower limb muscle strength and also increased perceived exertion and leg fatigue at post-performance of the 1-min STS and 6MWT when compared to control group.

Our results found that recovered group exhibited decreased handgrip strength and a longer duration for the STS10 test when compared to control group. The handgrip strength test was used to investigate the upper limb muscle strength [24], whereas, the STS10 test was used to evaluate the lower limb muscle strength [26]. Furthermore, these tests could indicate physical performance, especially in older adults [24,26]. The decrease in muscle strength in the upper and lower limbs of older adults post-COVID-19 may be attributed to SARS-CoV-2 damaging skeletal muscle cells by attaching to ACE2 receptors on their surfaces. This interaction disrupts cellular functions, leading to tissue dysfunction and cell death [27-29]. Additionally, this mechanism could contribute to the muscle damage observed in post-COVID-19 patients [30]. In addition, a previous study found that patients with type 2 diabetes who had mild to moderate COVID-19 had lower muscle strength and higher fatigue than those who did not have COVID-19 infection [31]. These results occur due to patients with type 2 diabetes who had mild to moderate COVID-19 and had receded serum albumin levels [31]. A previous study reported that post-COVID-19 without prior musculoskeletal problems had a high prevalence of low physical performance and muscle weakness [32]. Furthermore, older adults with post-COVID-19 increased risk of musculoskeletal problems due to the combined effect of viral infection and preexisting age-related declines in muscle mass and function [21,33]. Our results are consistent with previous studies, in finding that adults with post-COVID-19 showed decreased handgrip and quadriceps muscle strength [20,22]. According, the present study indicated that recovered group had reduced upper and lower limb muscle strength. To provide a broader context for our findings, it is valuable to integrate existing research on recovery from COVID-19 and other infectious diseases. Comparative studies can offer insights into whether the observed muscle strength reductions and changes in physical performance are specific to COVID-19 or if they are common across various infectious diseases. For instance, research on recovery from diseases like influenza or severe acute respiratory syndrome (SARS) may reveal similar patterns of muscle weakness and functional decline. A study by Ong et al. [34] demonstrated that patients recovering from SARS experienced prolonged muscle weakness, which was attributed to both the direct effects of the virus and the prolonged immobilization during illness. Similarly, research on post-viral fatigue syndrome following influenza has shown that muscle strength and physical performance can remain impaired long after the acute phase of the disease [35]. By comparing these findings with those from COVID-19 recovery studies, we can assess whether the muscle strength reductions observed in our study are unique to COVID-19 or part of a broader trend seen in post-infectious recovery.

The control group and recovered group showed increased blood pressure, HR, and reduced SpO2 at post-performance of the 1-min STS test and 6MWT. In addition, our results found differences in repetitions of the 1-min STS test and the distance of the 6MWT between the control group and recovered group. Moreover, the recovered group had significantly increased RPE and leg fatigue when compared to control group. These findings suggested the recovered group experiences reductions in some parameters of cardiorespiratory performance. Several studies reported that fatigue and exercise intolerance were found in adults with post-COVID-19 [36]. These responses occurred due to post-COVID-19, associated with muscular impairment, resulting in decreased fitness [37]. Moreover, the mechanism of exercise intolerance in post-COVID-19 may be involved in the cardiorespiratory pathway [38]. Additionally, previous studies reported a decreased repetitions of post-1-min STS as indicated by RPE and leg fatigue in post-COVID-19 [20]. These results are consistent with our own finding; we found recovered group had decreased repetitions of a-1-min STS and increased RPE and leg fatigue when compared with the control group. Our study has shown that transient increases in blood pressure following physical activity are common and often within normal physiological ranges. A previous study found that while blood pressure may rise post-exercise, it typically returns to baseline levels within a short period [39]. Additionally, comparisons with studies involving other populations or disease groups can provide further insights. For instance, individuals with cardiovascular conditions may experience different blood pressure responses to exercise compared to those without such conditions [40]. To enhance our understanding, future research could focus on the implications of these blood pressure changes for post-COVID-19 patients. Investigating whether these changes are associated with increased cardiovascular risk or if they are simply a transient response to physical exertion will be crucial. This approach will help determine whether specific recommendations or interventions are necessary to manage blood pressure in this population effectively.

Conclusions

This study indicated that the recovered group had reduced muscle strength and exercise tolerance when compared with the control group. These findings highlight the urgent need for targeted rehabilitation programs tailored to post-COVID-19 patients. Such programs should incorporate resistance training, aerobic exercises, and respiratory therapy to address both muscle weakness and cardiorespiratory limitations.

Limitation of this study

This study may be limited by some variables that impact muscle strength and cardiorespiratory parameters, including physical activity levels and anthropometric profiles. Therefore, future studies should consider these variables in the inclusion criteria.

Notes

CONFLICTS OF INTEREST

No potential conflict of interest relevant to this article was reported.

FUNDING INFORMATION

This research was funded by the Thailand Science Research and Innovation funds and the University of Phayao (Grant No. FF66-UoE009).

AUTHOR CONTRIBUTION

Conceptualization: Amput P. Data curation: Amput P, Wongphon S. Funding acquisition: Amput P. Investigation: Amput P, Wongphon S. Methodology: Amput P, Wongphon S. Writing – original draft: Amput P, Wongphon S. Writing – review and editing: Amput P. Approval of final manuscript: all authors.

References

1. Ozma MA, Maroufi P, Khodadadi E, Köse Ş, Esposito I, Ganbarov K, et al. Clinical manifestation, diagnosis, prevention and control of SARS-CoV-2 (COVID-19) during the outbreak period. Infez Med 2020;28:153–65.
2. Li LQ, Huang T, Wang YQ, Wang ZP, Liang Y, Huang TB, et al. COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol 2020;92:577–83.
3. Jacobs LG, Gourna Paleoudis E, Lesky-Di Bari D, Nyirenda T, Friedman T, Gupta A, et al. Persistence of symptoms and quality of life at 35 days after hospitalization for COVID-19 infection. PLoS One 2020;15e0243882.
4. Sagarra-Romero L, Viñas-Barros A. COVID-19: short and long-term effects of hospitalization on muscular weakness in the elderly. Int J Environ Res Public Health 2020;17:8715.
5. Van Aerde N, Van den Berghe G, Wilmer A, Gosselink R, Hermans G, ; COVID-19 Consortium. Intensive care unit acquired muscle weakness in COVID-19 patients. Intensive Care Med 2020;46:2083–5.
6. Ferrandi PJ, Alway SE, Mohamed JS. The interaction between SARS-CoV-2 and ACE2 may have consequences for skeletal muscle viral susceptibility and myopathies. J Appl Physiol (1985) 2020;129:864–7.
7. Dos Santos PK, Sigoli E, Bragança LJG, Cornachione AS. The musculoskeletal involvement after mild to moderate COVID-19 infection. Front Physiol 2022;13:813924.
8. Leung TW, Wong KS, Hui AC, To KF, Lai ST, Ng WF, et al. Myopathic changes associated with severe acute respiratory syndrome: a postmortem case series. Arch Neurol 2005;62:1113–7.
9. Aiyegbusi OL, Hughes SE, Turner G, Rivera SC, McMullan C, Chandan JS, et al, ; TLC Study Group. Symptoms, complications and management of long COVID: a review. J R Soc Med 2021;114:428–42.
10. Stavem K, Ghanima W, Olsen MK, Gilboe HM, Einvik G. Persistent symptoms 1.5-6 months after COVID-19 in non-hospitalised subjects: a population-based cohort study. Thorax 2021;76:405–7.
11. Vanichkachorn G, Newcomb R, Cowl CT, Murad MH, Breeher L, Miller S, et al. Post-COVID-19 Syndrome (Long Haul Syndrome): description of a multidisciplinary clinic at mayo clinic and characteristics of the initial patient cohort. Mayo Clin Proc 2021;96:1782–91.
12. Stavem K, Ghanima W, Olsen MK, Gilboe HM, Einvik G. Prevalence and determinants of fatigue after COVID-19 in non-hospitalized subjects: a population-based study. Int J Environ Res Public Health 2021;18:2030.
13. Amenta EM, Spallone A, Rodriguez-Barradas MC, El Sahly HM, Atmar RL, Kulkarni PA. Postacute COVID-19: an overview and approach to classification. Open Forum Infect Dis 2020;7:ofaa509.
14. Rudroff T, Fietsam AC, Deters JR, Bryant AD, Kamholz J. Post-COVID-19 fatigue: potential contributing factors. Brain Sci 2020;10:1012.
15. Miyazato Y, Morioka S, Tsuzuki S, Akashi M, Osanai Y, Tanaka K, et al. Prolonged and late-onset symptoms of Coronavirus Disease 2019. Open Forum Infect Dis 2020;7:ofaa507.
16. Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med 2021;27:626–31.
17. Yelin D, Margalit I, Yahav D, Runold M, Bruchfeld J. Long COVID-19-it’s not over until? Clin Microbiol Infect 2021;27:506–8.
18. Romero Starke K, Reissig D, Petereit-Haack G, Schmauder S, Nienhaus A, Seidler A. The isolated effect of age on the risk of COVID-19 severe outcomes: a systematic review with meta-analysis. BMJ Glob Health 2021;6e006434.
19. Zhang H, Wu Y, He Y, Liu X, Liu M, Tang Y, et al. Age-related risk factors and complications of patients with COVID-19: a population-based retrospective study. Front Med (Lausanne) 2022;8:757459.
20. Paneroni M, Simonelli C, Saleri M, Bertacchini L, Venturelli M, Troosters T, et al. Muscle strength and physical performance in patients without previous disabilities recovering from COVID-19 pneumonia. Am J Phys Med Rehabil 2021;100:105–9.
21. Welch C, Greig C, Masud T, Wilson D, Jackson TA. COVID-19 and acute sarcopenia. Aging Dis 2020;11:1345–51.
22. Tanriverdi A, Savci S, Kahraman BO, Ozpelit E. Extrapulmonary features of post-COVID-19 patients: muscle function, physical activity, mood, and sleep quality. Ir J Med Sci 2022;191:969–75.
23. Barbosa MH, Bolina AF, Luiz RB, de Oliveira KF, Virtuoso JS Jr, Rodrigues RA, et al. Body mass index as discriminator of the lean mass deficit and excess body fat in institutionalized elderly people. Geriatr Nurs 2015;36:202–6.
24. Segura-Ortí E, Martínez-Olmos FJ. Test-retest reliability and minimal detectable change scores for sit-to-stand-to-sit tests, the six-minute walk test, the one-leg heel-rise test, and handgrip strength in people undergoing hemodialysis. Phys Ther 2011;91:1244–52.
25. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111–7.
26. Balachandran AT, Vigotsky AD, Quiles N, Mokkink LB, Belio MA, Glenn JM. Validity, reliability, and measurement error of a sit-to-stand power test in older adults: a pre-registered study. Exp Gerontol 2021;145:111202.
27. Disser NP, De Micheli AJ, Schonk MM, Konnaris MA, Piacentini AN, Edon DL, et al. Musculoskeletal consequences of COVID-19. J Bone Joint Surg Am 2020;102:1197–1204.
28. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271–80.e8.
29. Benton DJ, Wrobel AG, Xu P, Roustan C, Martin SR, Rosenthal PB, et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature 2020;588:327–30.
30. Montes-Ibarra M, Oliveira CLP, Orsso CE, Landi F, Marzetti E, Prado CM. The impact of long COVID-19 on muscle health. Clin Geriatr Med 2022;38:545–57.
31. Mittal J, Ghosh A, Bhatt SP, Anoop S, Ansari IA, Misra A. High prevalence of post COVID-19 fatigue in patients with type 2 diabetes: a case-control study. Diabetes Metab Syndr 2021;15:102302.
32. Akbarialiabad H, Taghrir MH, Abdollahi A, Ghahramani N, Kumar M, Paydar S, et al. Long COVID, a comprehensive systematic scoping review. Infection 2021;49:1163–86.
33. Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al, ; ISARIC4C investigators. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 2020;369:m1985.
34. Ong KC, Ng AW, Lee LS, Kaw G, Kwek SK, Leow MK, et al. Pulmonary function and exercise capacity in survivors of severe acute respiratory syndrome. Eur Respir J 2004;24:436–42.
35. Reeves WC, Lloyd A, Vernon SD, Klimas N, Jason LA, Bleijenberg G, et al, ; International Chronic Fatigue Syndrome Study Group. Identification of ambiguities in the 1994 chronic fatigue syndrome research case definition and recommendations for resolution. BMC Health Serv Res 2003;3:25.
36. Jennings G, Monaghan A, Xue F, Mockler D, Romero-Ortuño R. A systematic review of persistent symptoms and residual abnormal functioning following acute COVID-19: ongoing symptomatic phase vs. post-COVID-19 syndrome. J Clin Med 2021;10:5913.
37. Jahn K, Sava M, Sommer G, Schumann DM, Bassetti S, Siegemund M, et al. Exercise capacity impairment after COVID-19 pneumonia is mainly caused by deconditioning. Eur Respir J 2021;59:2101136.
38. Ferreira EVM, Oliveira RKF. Mechanisms of exercise intolerance after COVID-19: new perspectives beyond physical deconditioning. J Bras Pneumol 2021;47e20210406.
39. Fagard RH, Cornelissen VA. Effect of exercise on blood pressure control in hypertensive patients. Eur J Cardiovasc Prev Rehabil 2007;14:12–7.
40. Lavie CJ, Arena R, Swift DL, Johannsen NM, Sui X, Lee DC, et al. Exercise and the cardiovascular system: clinical science and cardiovascular outcomes. Circ Res 2015;117:207–19.

Article information Continued

Table 1.

Characteristics of the older adults with and without recovery from mild COVID-19

Variable Older adults without COVID-19 (n=40, F=20, M=20) Older adults with recovery from mild COVID-19 (n=40, F=20, M=20) p-value
Age (yr) 70.43±5.31 68.65±5.03 0.86
Weight (kg) 52.58±7.56 54.75±6.46 0.63
Height (cm) 157.20±0.08 159.32±0.08 0.49
BMI (kg/m2) 21.20±1.89 21.52±1.43 0.08
SBP (mmHg) 134.15±11.99 125.05±12.47 0.43
DBP (mmHg) 76.08±8.12 75.38±10.56 0.13
HR (bpm) 80.68±9.86 78.93±10.32 0.40
SpO2 (%) 97.60±1.06 97.43±1.06 0.92

Values are presented as mean±standard deviation.

COVID-19, coronavirus disease 2019; F, female; M, male; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; SpO2, pulse oxygen saturation.

Table 2.

The comparison between muscle strength, repetitions of a 1-min STS, and distance of the 6MWT in older adults with and without recovery from mild COVID-19

Variable Older adults without COVID-19 Older adults with recovery from mild COVID-19 p-value
HGS (kg) 24.73±6.99 22.03±4.36 0.041
STS10 (s) 25.15±6.11 33.40±7.56 <0.001
Repetitions of a 1-min STS (n) 31.38±4.89 21.25±3.64 <0.001
Distance of the 6MWT (m) 421.68±8.28 384.35±6.17 <0.001

Values are presented as mean±standard deviation.

1-min STS, 1-minute sit-to-stand; 6MWT, 6-minute walk test; COVID-19, coronavirus disease 2019; HGS=handgrip strength; STS10, sit-to-stand test.

Table 3.

Impacts of 1-min STS and 6MWT on cardiorespiratory parameters in older adults with and without recovery from mild COVID-19

Variable Older adults without COVID-19 Older adults with recovery from mild COVID-19 p-value
1-min STS
 SBP baseline (mmHg) 131.05±10.93 128.28±11.95 0.67
 SBP post-test (mmHg) 138.03±10.76 134.75±10.10 0.72
 DBP baseline (mmHg) 79.43±9.34 79.30±8.29 0.71
 DBP post-test (mmHg) 78.88±7.84 80.65±10.29 0.24
 HR baseline (bpm) 77.83±9.44 78.10±10.58 0.25
 HR post-test (bpm) 85.48±11.05 84.38±12.59 0.37
 SpO2 baseline (%) 97.38±1.10 97.00±0.99 0.20
 SpO2 post-test (%) 96.58±1.08 96.15±0.89 0.20
 RPE post-test 7.43±1.20 8.95±1.01 0.01
 Leg fatigue post-test 1.49±1.13 3.00±1.04 0.03
6MWT
 SBP baseline (mmHg) 132.83±13.60 133.93±9.71 0.39
 SBP post-test (mmHg) 140.85±6.43 141.25±5.41 0.13
 DBP baseline (mmHg) 78.10±7.54 78.25±8.61 0.24
 DBP post-test (mmHg) 82.40±9.24 84.75±8.68 0.40
 HR baseline (bpm) 76.68±10.05 76.23±11.60 0.25
 HR post-test (bpm) 81.50±12.76 83.70±11.64 0.60
 SpO2 baseline (%) 97.43±1.47 97.70±1.11 0.21
 SpO2 post-test (%) 97.05±1.11 97.33±0.83 0.19
 RPE post-test 7.63±1.37 12.05±1.63 <0.001
 Leg fatigue post-test 1.71±0.88 5.28±0.91 <0.001

Values are presented as mean±standard deviation.

1-min STS, 1-minute sit-to-stand; 6MWT, 6-minute walk test; COVID-19, coronavirus disease 2019; SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; SpO2, pulse oxygen saturation; RPE, rate of perceived exertion.